Overview

The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients

Eligibility

Inclusion Criteria:

• 1\. Age 18-85 years
• 2\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
• 3\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
• 4\. Voluntarily provided written informed consent

Exclusion Criteria:

• 1\. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)
• 2\. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)
• 3\. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib)
• 4\. Active tuberculosis or active infectious diseases requiring systemic treatment
• 5\. Pregnancy, lactation, or refusal to use contraception during the study
• 6\. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due
• to:Non-adherence or Severe adverse reactions
• 7\. Other conditions contraindicating participation per investigator judgment